Sr.
No. |
Particulars |
Quarter
Ended
30.09.2007
(Audited)
|
Corresponding
Quarter Ended
30.09.2006
(Unaudited)
|
Year
Ended
30.09.2007
18 Months
(Audited)
|
Year
Ended
31.03.2006
12 Months
(Audited) |
1.
|
Gross
Sales |
2157 |
3316 |
14983 |
13528 |
| . |
Less:
Excise Duty |
110 |
188 |
812 |
696 |
| . |
Net
Sales |
2047 |
3128 |
14171 |
12832 |
| 2. |
Other
Income |
62 |
75 |
393 |
1449 |
|
Total
Income |
2109 |
3203 |
14563 |
14281 |
| 3. |
Total
Expenditure |
2956 |
3238 |
16962 |
12662 |
| . |
a)
(Increase) / Decrease in Stocks |
438 |
936 |
2427 |
344 |
| . |
b)
Material Consumed |
1168 |
1630 |
9513 |
8745 |
| . |
c)
Employee Cost |
311 |
216 |
1704 |
1049 |
| . |
d)
Operational and Administrative Expenses |
1039 |
456 |
3318 |
2524 |
| 4. |
Profit / (Loss) before Interest, Depreciation and Tax |
(847) |
(35) |
(2398) |
1619 |
| 5. |
Finance Cost (Net) |
35 |
165 |
1145 |
751 |
| 6. |
Profit
/ (Loss) after Interest, but before Depreciation and Tax |
(882) |
(200) |
(3543) |
868 |
| 7. |
Depreciation |
357 |
351 |
2123 |
1374 |
| 8. |
Profit
/ (Loss) before Tax |
(1239) |
(551) |
(5666) |
(506) |
| 9. |
Provision
for Fringe benefit Tax |
3 |
3 |
25 |
4 |
| 10. |
Profit
/ (Loss) after Tax |
(1242) |
(554) |
(5691) |
(510) |
| 11. |
Paid
up Equity Share Capital (Face Value Rs.10/- each) |
3349 |
3225 |
3349 |
2685 |
| 12. |
Reserves
excluding Revaluation Reserves |
--- |
--- |
--- |
6809 |
| 13. |
EPS for
the period, for the year to date and for the Previous year |
. |
. |
. |
. |
| . |
Basic
(Rs.) |
(3.73) |
(1.78) |
(17.14) |
(2.19) |
| . |
Diluted
(Rs.) |
(3.41) |
(1.11) |
(15.65) |
(1.44) |
| 14. |
Aggregate of Non-Promoters Shareholding |
. |
. |
. |
. |
| . |
Number of Shares
Percentage of Shareholding |
22966528
68.58%
|
22803528
70.72%
|
22966528
68.58% |
17569128
65.43% |
Notes
:
1. The above results were
reviewed by the Audit Committee and taken on record by the Board of Directors of
the Company at it's meeting held
on 9th January 2008.
2. The current year
figures are for 18 months and hence are not comparable with the previous year's
figures.
3. Previous period
figures have been regrouped/rearranged wherever necessary to confirm to the
current period's classification.
4. Auditors observation:
Investments and Advances made to
Subsidiary Company, Kopran Reserch Laboratories Ltd amounting to Rs. 6504.77
Lacs and Joint
Venture, Golbalpharma Co. LLC amounting to Rs. 1196.56 Lacs
which in the opinion of the Auditors are doubtful. In the opinion of the
Management since the Subsidiary Company, Kopran Research
Laboratories Ltd is proposed to be merged and investments in Joint Venture,
Global Pharma Co.LLC are made for long term period hence no
provision is required to be made.
5. The company has not received any complaints from the shareholders
during the quarter ended September, 2007.
For and on behalf of the Board of
Directors ....
Surendra
Somani
Executive Vice Chairman
Place: Mumbai
Date : 9th JANUARY, 2008
______________________________________________________________________
For more detail information, Contact
us.
